File Download
  Links for fulltext
     (May Require Subscription)

Article: Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery

TitleHuman Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery
Authors
Keywordsanticancer therapy
cardiotoxicity
human induced pluripotent cells
cardiomyocytes
pharmacogenomics
Issue Date2021
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology
Citation
Frontiers in Pharmacology, 2021, v. 12, p. article no. 650039 How to Cite?
AbstractAnticancer chemotherapies have been shown to produce severe side effects, with cardiotoxicity from anthracycline being the most notable. Identifying risk factors for anticancer therapy-induced cardiotoxicity in cancer patients as well as understanding its underlying mechanism is essential to improving clinical outcomes of chemotherapy treatment regimens. Moreover, cardioprotective agents against anticancer therapy-induced cardiotoxicity are scarce. Human induced pluripotent stem cell technology offers an attractive platform for validation of potential single nucleotide polymorphism with increased risk for cardiotoxicity. Successful validation of risk factors and mechanism of cardiotoxicity would aid the development of such platform for novel drug discovery and facilitate the practice of personalized medicine.
Persistent Identifierhttp://hdl.handle.net/10722/302362
ISSN
2023 Impact Factor: 4.4
2023 SCImago Journal Rankings: 1.066
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKeung, W-
dc.contributor.authorCheung, YF-
dc.date.accessioned2021-09-06T03:31:12Z-
dc.date.available2021-09-06T03:31:12Z-
dc.date.issued2021-
dc.identifier.citationFrontiers in Pharmacology, 2021, v. 12, p. article no. 650039-
dc.identifier.issn1663-9812-
dc.identifier.urihttp://hdl.handle.net/10722/302362-
dc.description.abstractAnticancer chemotherapies have been shown to produce severe side effects, with cardiotoxicity from anthracycline being the most notable. Identifying risk factors for anticancer therapy-induced cardiotoxicity in cancer patients as well as understanding its underlying mechanism is essential to improving clinical outcomes of chemotherapy treatment regimens. Moreover, cardioprotective agents against anticancer therapy-induced cardiotoxicity are scarce. Human induced pluripotent stem cell technology offers an attractive platform for validation of potential single nucleotide polymorphism with increased risk for cardiotoxicity. Successful validation of risk factors and mechanism of cardiotoxicity would aid the development of such platform for novel drug discovery and facilitate the practice of personalized medicine.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology-
dc.relation.ispartofFrontiers in Pharmacology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectanticancer therapy-
dc.subjectcardiotoxicity-
dc.subjecthuman induced pluripotent cells-
dc.subjectcardiomyocytes-
dc.subjectpharmacogenomics-
dc.titleHuman Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery-
dc.typeArticle-
dc.identifier.emailKeung, W: wkeung@hku.hk-
dc.identifier.emailCheung, YF: xfcheung@hku.hk-
dc.identifier.authorityKeung, W=rp01887-
dc.identifier.authorityCheung, YF=rp00382-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fphar.2021.650039-
dc.identifier.pmid33953683-
dc.identifier.pmcidPMC8090862-
dc.identifier.scopuseid_2-s2.0-85105129629-
dc.identifier.hkuros324839-
dc.identifier.volume12-
dc.identifier.spagearticle no. 650039-
dc.identifier.epagearticle no. 650039-
dc.identifier.isiWOS:000646174700001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats